For years, EDC has allowed sponsors and CROs to make great strides toward eliminating the burdens of paper-based data management. Now eSource, by extending eClinical functionality to the site level, is on the cusp of finishing the job. This technology has brought about unprecedented efficiencies in data capture and monitoring – and with its benefits already out on the market, sponsors and CROs will need to dive in fast in order to maintain their competitive edge.
It’s an exciting time for the industry. What does the future hold for eSource, and what are we doing at Medrio help define that future?
Signs point to an eSource revolution
As the industry continues to broaden its embrace of clinical trial technology, the writing is on the wall: eSource is an essential component of the future of clinical research. Careful industry observers will notice a few things that make this clear:
- Historical clues – While sponsors, CROs, and sites have already yielded major benefits from eSource, adoption has not yet been as swift as it could be. The explanation for this rests largely at the site level, where staff can be wary of technology alternatives to the paper-based data entry process to which they’re long accustomed.1 If this sounds familiar, it’s because the industry has seen it before – until relatively recently there was resistance among data managers, motivated by similar concerns, to adopting EDC. But history repeats itself in more ways than one: Just as improvements to EDC have caused skepticism to fade and adoption to soar, recent cutting-edge enhancements are poised to have a similar effect with eSource.
- Regulatory support – It didn’t take long for the FDA to recognize the revolutionary potential of eSource, and to get on board. As early as 2013, they released guidance promoting adoption of the technology, and last year expanded its embrace of electronic solutions in clinical trials to include technology such as electronic signatures.
What’s Medrio doing about it?
We’re no stranger to the eSource space, having released one of the first mobile tablet apps for eSource several years ago and enhanced it on a continuous basis since then. This has already made Medrio eSource a key resource for organizations as the technology nears the precipice of becoming a new standard in clinical research. With years of enhancements under our belt, the platform has already shown site staff around the world what they can achieve with eSource, thereby mitigating skepticism and facilitating the revolution.
Now it’s time to go further. We see Medrio eSource users as early adopters of a technology that will soon be viewed across the industry as essential to data management and monitoring, and see it as our mission to reward their foresight with the most robust and user-friendly platform on the market. With this in mind, we’ve released new enhancements to navigation and form visibility in the platform, and infused the Medrio Product team with designated eSource experts who have spent years studying the industry’s needs and reservations related to the technology and facilitating its implementation at sites across the globe. This is what we have in common with organizations currently moving to adopt eSource: the imperative to take action early, to be innovators rather than imitators.
eSource equips organizations with efficiencies that lead to lower margins and higher trial volume, and those who act now will be ahead of the game when the revolution takes off. As an early player in the eSource space, we couldn’t be more excited to see this happen.
1 Mitchell, John W.; The need for – and barriers to – adopting eSource; The CenterWatch Monthly; February 2017